Effect of probiotics on digestibility and immunity in infants: A study protocol for a randomized controlled trial
- PMID: 28383398
- PMCID: PMC5411182
- DOI: 10.1097/MD.0000000000005953
Effect of probiotics on digestibility and immunity in infants: A study protocol for a randomized controlled trial
Abstract
The gastrointestinal (GI) tract of a fetus in utero is sterile but it becomes colonized with environmental microorganisms shortly after birth. Since the gut microbiota undergoes substantial changes in early life, healthy gut microflora is essential to an infant's gut health and immune system and probably also has an effect on overall health status in later life. Probiotics, defined as viable microbial preparations that have a beneficial effect on the health of the host, represent a rapidly expanding field. Although randomized controlled trials using probiotics in infants have shown promising results in the prevention and treatment of common diseases such as diarrhea and allergy, little is known about whether probiotics could offer benefits to healthy infants. We have designed a randomized controlled trial to test the hypothesis that an oral preparation of probiotics is superior to placebo in improving digestive and immune function in healthy infants.The trial will be a randomized, double-blind, placebo-controlled, 2-parallel-group study in Shanghai, China. After a 2-week run-in period, 200 exclusively formula-fed healthy infants aged 4 to 6 months will be randomly allocated to receive either a probiotic product containing Bifidobacterium infantis R0033, Bifidobacterium bifidum R0071, and Lactobacillus helveticus R0052 or an identical placebo once daily for 4 weeks and will be followed up for 8 weeks. The duration of the subject's participation will be 14 weeks, with a total of 5 visits: inclusion (Visit 1, Day 1), start of intervention (V2, D15), end of intervention (V3, D44), and follow-up (V4 and V5, D72 and D100). Stool and saliva samples will be collected at the first 3 visits to measure microbial populations and secretory immunoglobulin A (SIgA), respectively. Physical examination will be performed at each visit, and tolerance records will be completed 1 day prior to each visit. The primary endpoints will be the changes in the composition of fecal microbiota, particularly the Bifidobacterium bifidum population. The secondary endpoints will include the change in salivary SIgA level, growth parameters, digestive tolerance, and adverse events.An effective, practical, and acceptable probiotic intervention in manipulating the gut microbiota and boosting the immune system in formula-fed infants would represent a major clinical advance. The administration of probiotic supplementation or follow-on formula to infant may be associated with some clinic benefits.
Conflict of interest statement
The authors have no conflicts of interest to disclose.
Figures
Similar articles
-
Probiotics maintain intestinal secretory immunoglobulin A levels in healthy formula-fed infants: a randomised, double-blind, placebo-controlled study.Benef Microbes. 2019 Oct 14;10(7):729-739. doi: 10.3920/BM2019.0025. Epub 2019 Jul 24. Benef Microbes. 2019. PMID: 31965842 Clinical Trial.
-
Modulatory effect of three probiotic strains on infants' gut microbial composition and immunological parameters on a placebo-controlled, double-blind, randomised study.Benef Microbes. 2018 Jun 15;9(4):573-584. doi: 10.3920/BM2017.0132. Epub 2018 May 4. Benef Microbes. 2018. PMID: 29726280 Clinical Trial.
-
Safety and tolerance of three probiotic strains in healthy infants: a multi-centre randomized, double-blind, placebo-controlled trial.Benef Microbes. 2017 Aug 24;8(4):569-578. doi: 10.3920/BM2017.0009. Epub 2017 May 30. Benef Microbes. 2017. PMID: 28555502 Clinical Trial.
-
Probiotics for the prevention of pediatric antibiotic-associated diarrhea.Cochrane Database Syst Rev. 2015 Dec 22;(12):CD004827. doi: 10.1002/14651858.CD004827.pub4. Cochrane Database Syst Rev. 2015. Update in: Cochrane Database Syst Rev. 2019 Apr 30;4:CD004827. doi: 10.1002/14651858.CD004827.pub5. PMID: 26695080 Updated. Review.
-
Probiotics for the prevention of pediatric antibiotic-associated diarrhea.Cochrane Database Syst Rev. 2011 Nov 9;(11):CD004827. doi: 10.1002/14651858.CD004827.pub3. Cochrane Database Syst Rev. 2011. Update in: Cochrane Database Syst Rev. 2015 Dec 22;(12):CD004827. doi: 10.1002/14651858.CD004827.pub4. PMID: 22071814 Updated. Review.
Cited by
-
Assessment trial of the effect of enteral insulin on the preterm infant intestinal microbiota.Pediatr Res. 2024 Mar;95(4):1117-1123. doi: 10.1038/s41390-023-02917-3. Epub 2023 Dec 12. Pediatr Res. 2024. PMID: 38086952 Clinical Trial.
-
MAMI: a comprehensive database of mother-infant microbiome and probiotic resources.Nucleic Acids Res. 2024 Jan 5;52(D1):D738-D746. doi: 10.1093/nar/gkad813. Nucleic Acids Res. 2024. PMID: 37819042 Free PMC article.
-
Precision sirolimus dosing in children: The potential for model-informed dosing and novel drug monitoring.Front Pharmacol. 2023 Mar 20;14:1126981. doi: 10.3389/fphar.2023.1126981. eCollection 2023. Front Pharmacol. 2023. PMID: 37021042 Free PMC article. Review.
-
Clinical study on sequential treatment of severe diarrhea irritable bowel syndrome with precision probiotic strains transplantation capsules, fecal microbiota transplantation capsules and live combined bacillus subtilis and enterococcus faecium capsules.Front Cell Infect Microbiol. 2022 Sep 28;12:1025889. doi: 10.3389/fcimb.2022.1025889. eCollection 2022. Front Cell Infect Microbiol. 2022. PMID: 36250045 Free PMC article.
-
Oral Administration of Lactobacillus helveticus LA401 and Lactobacillus gasseri LA806 Combination Attenuates Oesophageal and Gastrointestinal Candidiasis and Consequent Gut Inflammation in Mice.J Fungi (Basel). 2021 Jan 15;7(1):57. doi: 10.3390/jof7010057. J Fungi (Basel). 2021. PMID: 33467443 Free PMC article.
References
-
- Mackie RI, Sghir A, Gaskins HR. Developmental microbial ecology of the neonatal gastrointestinal tract. Am J Clin Nutr 1999;69:S1035–45. - PubMed
-
- Matamoros S, Gras-Leguen C, Le Vacon F, et al. Development of intestinal microbiota in infants and its impact on health. Trends Microbiol 2013;21:167–73. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources